

**AMENDMENTS TO THE CLAIMS**

Please **CANCEL** claim 8 without prejudice or disclaimer.

Please **AMEND** claim 7 as shown below.

Please **ADD** new claims 21-30 as shown below.

The following is a complete list of all claims in this application.

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Currently Amended) A method for treating a patient having intestinal mucosal damage comprising decreasing the mucosal damage of the ~~small~~ intestine by administering an effective dose of HGF to ~~[[a]]~~ the patient wherein the patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, and chronic infections of the bowel.
8. (Cancelled)
9. (Original) The method of claim 7 wherein the administration of HGF is performed systemically.
10. (Original) The method of claim 7 where the administration of HGF is performed lumenally.

11. (Original) The method of claim 7 wherein the effective dosage range of HGF is about 30  $\mu\text{g/kg}$  body weight/ day to about 300  $\mu\text{g/kg}$  body weight/day.
12. (Original) The method of claim 7 wherein the effective dose of HGF is about 150  $\mu\text{g/kg}$  body weight/day.
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (New) A method for treating a patient having intestinal mucosal damage comprising decreasing the mucosal damage of the intestine by administering an effective dose of HGF to the patient wherein the patient has a condition selected from the group consisting of immunologic disorders affecting the intestine, immunodeficiency syndromes affecting the intestine, and HIV.
22. (New) The method of claim 21, wherein the administration of HGF is performed systemically.
23. (New) The method of claim 21, wherein the administration of HGF is performed lumenally.
24. (New) The method of claim 21, wherein the effective dosage range of HGF is about 30  $\mu\text{g/kg}$  body weight/day to about 300  $\mu\text{g/kg}$  body weight/day.

25. (New) The method of claim 21, wherein the effective dose of HGF is about 150  $\mu\text{g/kg}$  body weight/day.
26. (New) A method for treating a patient having intestinal mucosal damage comprising decreasing the mucosal damage of the intestine by administering an effective dose of HGF to the patient wherein the effective dosage range of HGF is about 30  $\mu\text{g/kg}$  body weight/day to about 300  $\mu\text{g/kg}$  body weight/day.
27. (New) The method of claim 26, wherein the patient has a condition selected from the group consisting of Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the intestine, immunodeficiency syndromes affecting the intestine, and HIV.
28. (New) The method of claim 26, wherein the administration of HGF is performed systemically.
29. (New) The method of claim 26, wherein the administration of HGF is performed lumenally.
30. (New) The method of claim 26, wherein the effective of HGF is about 150  $\mu\text{g/kg}$  body weight/day.
31. (New) The method of claim 26, wherein the intestine includes the small intestine.
32. (New) The method of claim 21, wherein the intestine includes the small intestine.
33. (New) The method of claim 7, wherein the intestine includes the small intestine.